Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know

Oncology (Switzerland)

Volumn 84, Issue , 2013, Pages 34-39

  Kim, Yun Hwan ^a   Kim, Do Young ^b  

^a Korea University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Transarterial chemoembolization; Yttrium 90

Indexed keywords

SORAFENIB; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONFERENCE PAPER; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE;

EID: 84874376178     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345887     Document Type: Conference Paper

References (40)

1. Kudo M: Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer, in press.
2. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
3. Llovet JM, Ducreux M, Lencioni R, et al: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
4. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
5. Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH: Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 1343-1350.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
7. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.
8. Choi GH, Shim JH, Lee D, Kim KM, Ryu MH, Lim YS, Ryoo BY, Lee HC, Chung YH, Kang YK, Lee YS, Suh DJ: The optimal indication of sorafenib treatment in patients with advanced-stage hepatocellular carcinoma. Liver Cancer 2012; 1: 115.
9. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57: 821-829.
10. Sangro B, Inarrairaegui M, Bilbao JI: Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56: 464-473.
11. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL: Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90 Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010; 51: 1377-1385.
12. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK: Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24: 293-298.
13. Kao YH, Tan EH, Ng CE, Goh SW: Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med 2011; 25: 455-461.
14. Kennedy A, Nag S, Salem R, Murthy R, Mc-Ewan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23.
15. Wang SC, Bester L, Burnes JP, Clouston JE, Hugh TJ, Little AF, Padbury RT, Price D: Clinical care and technical recommendations for 90 yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010; 54: 178-187.
16. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK: Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: 583-592.
17. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C: Yttrium 90 radioembolization for intermediateadvanced hepatocarcinoma: A phase II study. Hepatology 2012, E-pub ahead of print.
18. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.
19. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival. Hepatology 2010; 52: 1741-1749.
20. Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH: Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1377-1384.
21. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
22. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R: Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20: 1121-1131.
23. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG: Treatment of unresectable hepatocellular carcinoma with use of 90 Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639.
24. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S: Resin 90 Ymicrosphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425.
25. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S, Nemcek AA Jr, Vogelzang R, Salem R: Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (Thera-Sphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29: 522-529.
26. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R: Treatment parameters and outcome in 680 treatments of internal radiation with resin 90 Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500.
27. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R: Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19: 691-697.
28. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK: Radiation pneumonitis after selective internal radiation treatment with intraarterial 90 yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33: 919-924.
29. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.
30. Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV: Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1697-1705.
31. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
32. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
33. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL: Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011; 81(suppl 1):158-164.
34. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
35. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R: Safety and efficacy of 90 Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
36. Fox RA, Klemp PF, Egan G, Mina LL, Burton MA, Gray BN: Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21: 463-467.
37. Wigg A, Wallington M: Yttrium 90 therapy for hepatocellular carcinoma: is it any better than conventional external beam radiotherapy? Hepatology 2012; 55: 981-982.
38. Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, Larson AC, Ryu RK, Sato KT, Lewandowski RJ, Omary RA, Salem R: Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 1375-1382.
39. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J: Radioembolization using 90 Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
40. Carr BI: Hepatic arterial 90 Yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10:S107-S110.